ArticleRSC chemical biology2022

A dual-responsive doxorubicin-indoximod conjugate for programmed chemoimmunotherapy.

Zhaoxuan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.